lansoprazole has been researched along with Triple Negative Breast Neoplasms in 1 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beebe, J | 1 |
| Josephraj, S | 1 |
| Wang, CJ | 1 |
| Danielson, J | 1 |
| Cui, Q | 1 |
| Huang, C | 1 |
| Barlow, L | 1 |
| Zhang, RH | 1 |
| Zhang, T | 1 |
| Nakshatri, H | 1 |
| Dong, Z | 1 |
| Li, X | 1 |
| Liu, JY | 1 |
| Zhang, JT | 1 |
1 other study available for lansoprazole and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Therapeutic Activity of the Lansoprazole Metabolite 5-Hydroxy Lansoprazole Sulfide in Triple-Negative Breast Cancer by Inhibiting the Enoyl Reductase of Fatty Acid Synthase.
Topics: Fatty Acid Synthases; Humans; Lansoprazole; Lipids; Oxidoreductases; Proton Pump Inhibitors; Sulfide | 2022 |